The chemical sector has been a brutal battlefield lately, but Black Rose Industries Ltd (BRIL) just dropped a financial bombshell that demands a closer look. While the broader industry gasps for air amidst fluctuating raw material costs, BRIL has clocked a massive 57.3% YoY growth in quarterly profit, reaching ₹9.41 crore in Q4 FY26.
Wait, it gets more interesting. The company didn’t just earn more; it earned better. The Operating Profit Margin (OPM) expanded significantly to 12.52% in the latest quarter, compared to a meager 2.73% in the same quarter last year. When a company manages to quadruple its margins in a year while facing global supply chain volatility, you know there is a deeper story hidden in the balance sheet.
Investors are waking up to a company that is almost debt-free (Debt to Equity of 0.01) and boasts a robust ROCE of 18.9%. With the board recommending a 125% dividend (₹1.25 per share), the management is clearly signaling confidence. However, beneath this polished surface lies a strategic shift: the exit from its Japanese subsidiary and a “plant closure” drama that was recently resolved.
1. At a Glance
Black Rose Industries is currently at a critical pivot point. For years, it operated as a hybrid animal—part high-volume chemical distributor and part specialized manufacturer. Today, the numbers tell us the manufacturing side is finally starting to flex its muscles. The company reported Sales of ₹104.04 crore for Q4 FY26, a healthy 25.5% jump from ₹82.89 crore in the previous quarter.
But let’s look at the red flags before we get too comfortable. The distribution business, which still accounts for a massive chunk of revenue, is inherently low-margin and exposed to the whims of foreign exchange. The company’s 5-year sales growth is a depressing -3.19%. This is not a “growth at all costs” story; it’s a turnaround story. The management is essentially trying to replace low-margin trading revenue with high-margin manufacturing output.
The “Drama Quotient” is also high here. In December 2025, the Gujarat Pollution Control Board (GPCB) ordered a closure of their Jhagadia plant. While the order was revoked within weeks after a payment of ₹3.80 lakh, it serves as a stark reminder of the regulatory risks inherent in the chemical business. Furthermore, the company is in the process of selling or closing its Japanese subsidiary, B.R. Chemicals Co., Ltd., which previously contributed significantly to the top line.
Is this a lean, mean, manufacturing machine in the making, or a distributor struggling to stay relevant? The jump in PAT from ₹4.40 crore in Dec 2025 to ₹9.41 crore in Mar 2026 suggests the former, but the volatile history of the chemical cycle warns us to keep our eyes wide open.
2. Introduction
Incorporated in 1990, Black Rose Industries has evolved from its textile roots (formerly Asia Fab Ltd) into a specialized chemical powerhouse. It holds the distinction of operating India’s first acrylamide manufacturing plant. This isn’t just a fancy title; acrylamide is a critical building block for water treatment, paper manufacturing, and enhanced oil recovery.
The company operates through three distinct verticals: Chemical Distribution, Manufacturing, and a small Renewable Energy arm. While distribution brings in the volume (around 61% of FY23 revenue), manufacturing is the crown jewel that provides the bottom-line “oomph.”
BRIL’s manufacturing facility in Jhagadia, Gujarat, is a massive setup with an installed capacity of 32,000 MTPA for acrylamide liquid. They are also scaling up in Polyacrylamide, targeting industries that are core to India’s infrastructure and environmental goals.
The recent Board meeting on May 13, 2026, was a marathon session. Not only did they approve the stellar Q4 results, but they also reappointed key leaders like Mrs. Shruti Jatia and Mr. Ambarish Daga. This stability at the top is crucial as the company navigates its exit from the Japanese market to focus intensely on domestic
